Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoying ZhangJWJue WangNWNa Wang

Discussion

Loading...

Member takes

Overview

Clinical trials report improved responses in relapsed DLBCL with CAR T-cell therapy and autologous stem cell transplantation, suggesting enhanced therapy effectiveness.

Key Points

  • This research assesses long-term efficacy and safety of CAR T-cell therapy and ASCT for relapsed/refractory DLBCL.
  • Conducted two single-arm clinical trials comparing CAR19/22 T-cell therapy and CAR19/22 with ASCT.
  • Analyzed outcomes from 124 R/R DLBCL patients enrolled from January 2018 to December 2020.
  • Utilized propensity score matching and inverse probability treatment weighting to control for confounders.
  • No significant toxicities observed within the first 30 days.
  • Trial B showed a higher overall response rate (84.48% vs. 54.24%, P<0.001).
  • Longest median overall survival in Trial B was 27.61 months compared to not reaching in Trial A.
  • Immunophenotypic changes: reduced Treg and expanded CD8+ T cells in the ASCT group.
  • Complete response at 3 months is a protective factor for long-term survival.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d925https://doi.org/10.1182/blood-2025-7243
View Full Paper
Ask AI
Bookmark
Share